Timothy Tree

Guy's Hospital — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

42h-index8.6kcitations165works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes and associated disorders(85), Immune Cell Function and Interaction(57), Diabetes Management and Research(49), Pancreatic function and diabetes(49), T-cell and B-cell Immunology(32)

Publications162 total

Genetic risk in extremely early onset type 1 diabetes
2025Open Access
Tracking GAD-specific T-cell expansions in Type 1 diabetes by intradermal GAD-Alum challenge
2025Open Access
Stratifying IL-2 therapy in ALS: integrating biomarkers – Authors' reply
The Lancet·2025· 1 cited
The minor spliceosome is a master immune regulator
2025Open Access
Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial
The Lancet·2025· 6 citedOpen Access
Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects
Diabetes/Metabolism Research and Reviews·2025· 2 citedOpen Access
Blood samples collected under anesthesia can be used as a source of non-diseased controls for immune-based assays
Frontiers in Immunology·2025Open Access
Author response for "Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects"
2025
Author response for "Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects"
2025
SAT-086 Tumour-infiltrating regulatory T cells engage Nrf2 signalling to support their metabolic adaptation in hepatocellular carcinoma
Journal of Hepatology·2025
SMART-ALERT study: continuous cardiac monitoring and real-time automated smartphone alerts for atrial fibrillation episodes
EP Europace·2025Open Access
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial
The Lancet·2025· 19 citedOpen Access
Author response for "Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects"
2025
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures
Nature·2025· 14 citedOpen Access
The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT
Efficacy and Mechanism Evaluation·2025Open Access
Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocol
Contemporary Clinical Trials Communications·2025· 1 citedOpen Access
Meeting Report: The Sixth International Sam Strober Workshop on Clinical Immune Tolerance
Transplantation·2025· 7 citedOpen Access
Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling
Immunity·2024· 17 citedOpen Access
Type 1 Diabetes Genetic Risk Contributes to Phenotypic Presentation in Monogenic Autoimmune Diabetes
Diabetes·2024· 5 citedOpen Access
Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial
Nature Medicine·2024· 37 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Mark Peakman(18), Bart O. Roep(16), Colin Dayan(10), Jennie H. M. Yang(9), John A. Todd(7), Linda S. Wicker(7), Clara Domingo‐Vila(6), Sefina Arif(6), Katie J. Doores(5), Marcin Ł. Pękalski(5), Ricardo C. Ferreira(5), Carl Graham(4), Jeffrey Seow(4), Michael H. Malim(4), Jennifer Tremble(4), Ania Skowera(4), Antony J. Cutler(4), Emily Pollock(4), Chris Wallace(4), Amanda J. Bishop(3)